Hemovigilance program-India
Akanksha Bisht1, Surinder Singh, Neelam Marwaha
1Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Ghaziabad, India.
Insights
India launched a national hemovigilance program on December 10, 2012, to monitor blood transfusion adverse reactions and ensure patient safety. This initiative, coordinated by the National Institute of Biologicals, aims for nationwide coverage by 2016.
Area of Science:
- Public Health
- Pharmacovigilance
- Medical Safety
Background:
- Blood transfusion services require robust monitoring systems to ensure patient safety.
- Adverse reactions to blood products can pose significant public health risks.
- India lacked a centralized system for hemovigilance prior to 2012.
Purpose of the Study:
- To establish a centralized hemovigilance program in India.
- To monitor and report adverse reactions associated with blood transfusion and administration of blood products.
- To promote patient safety and public health through improved blood product safety.
Main Methods:
- Launch of a national hemovigilance program on December 10, 2012.
- Inclusion of 60 medical colleges in the initial phase.
- Integration with the Pharmacovigilance Program of India (PvPI).
Main Results:
- A structured program for monitoring adverse reactions was established.
- The National Institute of Biologicals (NIB) designated as the National Coordinating Centre.
- Phased rollout aiming for enrollment of all medical colleges by 2016.
Conclusions:
- The establishment of a centralized hemovigilance program is crucial for patient safety in India.
- The program aims to create a global knowledge platform for hemovigilance at NIB.
- Nationwide implementation will enhance the safety and efficacy of blood transfusion services.
Abstract:
A centralized hemovigilance program to assure patient safety and to promote public health has been launched for the first time in India on Dec 10, 2012 in 60 medical colleges in the first phase along with a well-structured program for monitoring adverse reactions associated with blood transfusion and blood product administration. National Institute of Biologicals (NIB) will be the National Coordinating Centre for Hemovigilance. This program will be implemented under overall ambit of Pharmacovigilance Program of India (PvPI), which is being coordinated by Indian Pharmacopoeia Commission (IPC). All medical colleges of the country will be enrolled in this program by the year 2016 in order to have a National Centre of Excellence for Hemovigilance at NIB, which will act as a global knowledge platform.
More Related Videos
11:28Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose (Herpestes Auropunctatus) Sera for Use as an Oral Rabies Vaccination Biological Marker
Published on: May 31, 2019
05:35A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
Published on: January 19, 2024
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioequivalence studies: Biowaivers
Preventive Healthcare Services
Integrated Healthcare System
Viral Hepatitis I: Introduction
Secondary Healthcare System
